Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.66 |
| ▸ | JAK2 | O60674 | 8/20 | 0.66 |
| ▸ | FYN | P06241 | 5/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 2/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102515 | 0.89 | FYN (0.62) | JAK3JAK2FYNPTK2PIK3CD | |
| SCHEMBL4595046 | 0.84 | FYN (0.66) | FYNPIM1 | |
| SCHEMBL16784348 | 0.84 | FYN (0.66) | JAK3JAK2FYNPTK2PIM1 | |
| SCHEMBL4692793 | 0.84 | FYN (0.65) | JAK3JAK2FYNPTK2PIK3CD | |
| SCHEMBL4335453 | 0.84 | FYN (0.82) | JAK3JAK2FYNPTK2PIM1 | |
| SCHEMBL4338988 | 0.83 | BRAF (0.64) | JAK3JAK2FYN | |
| SCHEMBL4337397 | 0.82 | PIK3CG (0.62) | JAK3JAK2FYNPTK2PIK3CD | |
| SCHEMBL4332841 | 0.82 | FYN (0.69) | JAK3JAK2FYNPTK2PIK3CD | |
| SCHEMBL4338182 | 0.82 | FYN (0.69) | FYNPIM1 | |
| SCHEMBL4340112 | 0.80 | FYN (0.67) | JAK3JAK2FYNPTK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049539-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| WO-2007147647-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | DPYD, FLT1, PDXK | JAK3 145/4885JAK2 49/4885FYN 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.